nodes	percent_of_prediction	percent_of_DWPC	metapath
Dextropropoxyphene—CYP2C9—Teniposide—lymphatic system cancer	0.14	0.21	CbGbCtD
Dextropropoxyphene—CYP3A7—Vincristine—lymphatic system cancer	0.134	0.201	CbGbCtD
Dextropropoxyphene—CYP3A7-CYP3A51P—Vincristine—lymphatic system cancer	0.134	0.201	CbGbCtD
Dextropropoxyphene—CYP3A4—Cytarabine—lymphatic system cancer	0.0826	0.124	CbGbCtD
Dextropropoxyphene—CYP3A4—Teniposide—lymphatic system cancer	0.0814	0.122	CbGbCtD
Dextropropoxyphene—CYP3A4—Mitoxantrone—lymphatic system cancer	0.0569	0.0852	CbGbCtD
Dextropropoxyphene—CYP3A4—Vincristine—lymphatic system cancer	0.0392	0.0587	CbGbCtD
Dextropropoxyphene—Metabolic acidosis—Teniposide—lymphatic system cancer	0.0165	0.0498	CcSEcCtD
Dextropropoxyphene—Metabolic acidosis—Fludarabine—lymphatic system cancer	0.0145	0.0438	CcSEcCtD
Dextropropoxyphene—Digestion impaired—Fludarabine—lymphatic system cancer	0.00859	0.0259	CcSEcCtD
Dextropropoxyphene—Hepatic function abnormal—Teniposide—lymphatic system cancer	0.00543	0.0164	CcSEcCtD
Dextropropoxyphene—Coma—Fludarabine—lymphatic system cancer	0.00525	0.0158	CcSEcCtD
Dextropropoxyphene—Jaundice—Mechlorethamine—lymphatic system cancer	0.00483	0.0146	CcSEcCtD
Dextropropoxyphene—Cardiac failure congestive—Fludarabine—lymphatic system cancer	0.0046	0.0138	CcSEcCtD
Dextropropoxyphene—Visual disturbance—Fludarabine—lymphatic system cancer	0.0044	0.0133	CcSEcCtD
Dextropropoxyphene—Liver function test abnormal—Teniposide—lymphatic system cancer	0.00438	0.0132	CcSEcCtD
Dextropropoxyphene—Gastrointestinal haemorrhage—Fludarabine—lymphatic system cancer	0.00417	0.0126	CcSEcCtD
Dextropropoxyphene—Drug interaction—Carmustine—lymphatic system cancer	0.00396	0.0119	CcSEcCtD
Dextropropoxyphene—Liver function test abnormal—Fludarabine—lymphatic system cancer	0.00385	0.0116	CcSEcCtD
Dextropropoxyphene—Drug interaction—Vincristine—lymphatic system cancer	0.00378	0.0114	CcSEcCtD
Dextropropoxyphene—Coma—Carmustine—lymphatic system cancer	0.00336	0.0101	CcSEcCtD
Dextropropoxyphene—Coma—Vincristine—lymphatic system cancer	0.00321	0.00966	CcSEcCtD
Dextropropoxyphene—Acute coronary syndrome—Fludarabine—lymphatic system cancer	0.00317	0.00954	CcSEcCtD
Dextropropoxyphene—Myocardial infarction—Fludarabine—lymphatic system cancer	0.00315	0.00949	CcSEcCtD
Dextropropoxyphene—Arrhythmia—Teniposide—lymphatic system cancer	0.00293	0.00883	CcSEcCtD
Dextropropoxyphene—Visual impairment—Fludarabine—lymphatic system cancer	0.00278	0.00837	CcSEcCtD
Dextropropoxyphene—Cardiac failure congestive—Mitoxantrone—lymphatic system cancer	0.00274	0.00824	CcSEcCtD
Dextropropoxyphene—Gastrointestinal haemorrhage—Carmustine—lymphatic system cancer	0.00267	0.00804	CcSEcCtD
Dextropropoxyphene—Agitation—Teniposide—lymphatic system cancer	0.00263	0.00791	CcSEcCtD
Dextropropoxyphene—Arrhythmia—Fludarabine—lymphatic system cancer	0.00258	0.00776	CcSEcCtD
Dextropropoxyphene—Malnutrition—Fludarabine—lymphatic system cancer	0.00251	0.00756	CcSEcCtD
Dextropropoxyphene—Ataxia—Carmustine—lymphatic system cancer	0.00251	0.00756	CcSEcCtD
Dextropropoxyphene—Gastrointestinal haemorrhage—Mitoxantrone—lymphatic system cancer	0.00248	0.00747	CcSEcCtD
Dextropropoxyphene—Liver function test abnormal—Carmustine—lymphatic system cancer	0.00246	0.00742	CcSEcCtD
Dextropropoxyphene—Cardiac arrest—Vincristine—lymphatic system cancer	0.00242	0.0073	CcSEcCtD
Dextropropoxyphene—Ataxia—Vincristine—lymphatic system cancer	0.00239	0.00721	CcSEcCtD
Dextropropoxyphene—Confusional state—Teniposide—lymphatic system cancer	0.00235	0.00708	CcSEcCtD
Dextropropoxyphene—Hypersensitivity—Mechlorethamine—lymphatic system cancer	0.00233	0.00702	CcSEcCtD
Dextropropoxyphene—Acute coronary syndrome—Bleomycin—lymphatic system cancer	0.00232	0.007	CcSEcCtD
Dextropropoxyphene—Myocardial infarction—Bleomycin—lymphatic system cancer	0.00231	0.00696	CcSEcCtD
Dextropropoxyphene—Agitation—Fludarabine—lymphatic system cancer	0.00231	0.00695	CcSEcCtD
Dextropropoxyphene—Tachycardia—Teniposide—lymphatic system cancer	0.00228	0.00685	CcSEcCtD
Dextropropoxyphene—Hypotension—Teniposide—lymphatic system cancer	0.00218	0.00656	CcSEcCtD
Dextropropoxyphene—Convulsion—Fludarabine—lymphatic system cancer	0.00218	0.00655	CcSEcCtD
Dextropropoxyphene—Diarrhoea—Mechlorethamine—lymphatic system cancer	0.00216	0.00652	CcSEcCtD
Dextropropoxyphene—Discomfort—Fludarabine—lymphatic system cancer	0.00211	0.00636	CcSEcCtD
Dextropropoxyphene—Dyspnoea—Teniposide—lymphatic system cancer	0.00208	0.00626	CcSEcCtD
Dextropropoxyphene—Confusional state—Fludarabine—lymphatic system cancer	0.00207	0.00622	CcSEcCtD
Dextropropoxyphene—Vomiting—Mechlorethamine—lymphatic system cancer	0.00201	0.00606	CcSEcCtD
Dextropropoxyphene—Nervous system disorder—Fludarabine—lymphatic system cancer	0.00201	0.00605	CcSEcCtD
Dextropropoxyphene—Rash—Mechlorethamine—lymphatic system cancer	0.00199	0.00601	CcSEcCtD
Dextropropoxyphene—Dermatitis—Mechlorethamine—lymphatic system cancer	0.00199	0.006	CcSEcCtD
Dextropropoxyphene—Acute coronary syndrome—Vincristine—lymphatic system cancer	0.00193	0.00583	CcSEcCtD
Dextropropoxyphene—Myocardial infarction—Vincristine—lymphatic system cancer	0.00192	0.0058	CcSEcCtD
Dextropropoxyphene—Feeling abnormal—Teniposide—lymphatic system cancer	0.00192	0.00579	CcSEcCtD
Dextropropoxyphene—Drowsiness—Mitoxantrone—lymphatic system cancer	0.00191	0.00576	CcSEcCtD
Dextropropoxyphene—Gastrointestinal pain—Teniposide—lymphatic system cancer	0.00191	0.00574	CcSEcCtD
Dextropropoxyphene—Acute coronary syndrome—Mitoxantrone—lymphatic system cancer	0.00188	0.00568	CcSEcCtD
Dextropropoxyphene—Nausea—Mechlorethamine—lymphatic system cancer	0.00188	0.00566	CcSEcCtD
Dextropropoxyphene—Myocardial infarction—Mitoxantrone—lymphatic system cancer	0.00187	0.00564	CcSEcCtD
Dextropropoxyphene—Jaundice—Mitoxantrone—lymphatic system cancer	0.00186	0.00561	CcSEcCtD
Dextropropoxyphene—Abdominal pain—Teniposide—lymphatic system cancer	0.00184	0.00555	CcSEcCtD
Dextropropoxyphene—Hallucination—Carmustine—lymphatic system cancer	0.00184	0.00553	CcSEcCtD
Dextropropoxyphene—Dyspnoea—Fludarabine—lymphatic system cancer	0.00183	0.0055	CcSEcCtD
Dextropropoxyphene—Dyspepsia—Fludarabine—lymphatic system cancer	0.0018	0.00543	CcSEcCtD
Dextropropoxyphene—Visual impairment—Carmustine—lymphatic system cancer	0.00178	0.00536	CcSEcCtD
Dextropropoxyphene—Gastrointestinal disorder—Fludarabine—lymphatic system cancer	0.00177	0.00533	CcSEcCtD
Dextropropoxyphene—Hallucination—Vincristine—lymphatic system cancer	0.00175	0.00528	CcSEcCtD
Dextropropoxyphene—Constipation—Fludarabine—lymphatic system cancer	0.00175	0.00528	CcSEcCtD
Dextropropoxyphene—Bradycardia—Mitoxantrone—lymphatic system cancer	0.00175	0.00526	CcSEcCtD
Dextropropoxyphene—Eye disorder—Carmustine—lymphatic system cancer	0.00172	0.0052	CcSEcCtD
Dextropropoxyphene—Hypersensitivity—Teniposide—lymphatic system cancer	0.00172	0.00517	CcSEcCtD
Dextropropoxyphene—Feeling abnormal—Fludarabine—lymphatic system cancer	0.00169	0.00509	CcSEcCtD
Dextropropoxyphene—Asthenia—Teniposide—lymphatic system cancer	0.00167	0.00504	CcSEcCtD
Dextropropoxyphene—Arrhythmia—Carmustine—lymphatic system cancer	0.00165	0.00497	CcSEcCtD
Dextropropoxyphene—Cardiac disorder—Vincristine—lymphatic system cancer	0.00164	0.00493	CcSEcCtD
Dextropropoxyphene—Malnutrition—Carmustine—lymphatic system cancer	0.00161	0.00484	CcSEcCtD
Dextropropoxyphene—Diarrhoea—Teniposide—lymphatic system cancer	0.0016	0.00481	CcSEcCtD
Dextropropoxyphene—Mediastinal disorder—Vincristine—lymphatic system cancer	0.00159	0.00478	CcSEcCtD
Dextropropoxyphene—Coma—Methotrexate—lymphatic system cancer	0.00156	0.00469	CcSEcCtD
Dextropropoxyphene—Discomfort—Bleomycin—lymphatic system cancer	0.00155	0.00466	CcSEcCtD
Dextropropoxyphene—Arrhythmia—Mitoxantrone—lymphatic system cancer	0.00153	0.00462	CcSEcCtD
Dextropropoxyphene—Confusional state—Bleomycin—lymphatic system cancer	0.00151	0.00456	CcSEcCtD
Dextropropoxyphene—Vision blurred—Carmustine—lymphatic system cancer	0.00151	0.00456	CcSEcCtD
Dextropropoxyphene—Hypersensitivity—Fludarabine—lymphatic system cancer	0.00151	0.00455	CcSEcCtD
Dextropropoxyphene—Vomiting—Teniposide—lymphatic system cancer	0.00148	0.00447	CcSEcCtD
Dextropropoxyphene—Agitation—Carmustine—lymphatic system cancer	0.00148	0.00445	CcSEcCtD
Dextropropoxyphene—Asthenia—Fludarabine—lymphatic system cancer	0.00147	0.00443	CcSEcCtD
Dextropropoxyphene—Rash—Teniposide—lymphatic system cancer	0.00147	0.00443	CcSEcCtD
Dextropropoxyphene—Dermatitis—Teniposide—lymphatic system cancer	0.00147	0.00442	CcSEcCtD
Dextropropoxyphene—Headache—Teniposide—lymphatic system cancer	0.00146	0.0044	CcSEcCtD
Dextropropoxyphene—Agitation—Vincristine—lymphatic system cancer	0.00141	0.00425	CcSEcCtD
Dextropropoxyphene—Vision blurred—Mitoxantrone—lymphatic system cancer	0.00141	0.00424	CcSEcCtD
Dextropropoxyphene—Hypotension—Bleomycin—lymphatic system cancer	0.0014	0.00423	CcSEcCtD
Dextropropoxyphene—Diarrhoea—Fludarabine—lymphatic system cancer	0.0014	0.00422	CcSEcCtD
Dextropropoxyphene—Convulsion—Carmustine—lymphatic system cancer	0.00139	0.00419	CcSEcCtD
Dextropropoxyphene—Nausea—Teniposide—lymphatic system cancer	0.00138	0.00417	CcSEcCtD
Dextropropoxyphene—Dyspnoea—Bleomycin—lymphatic system cancer	0.00134	0.00403	CcSEcCtD
Dextropropoxyphene—Convulsion—Vincristine—lymphatic system cancer	0.00133	0.004	CcSEcCtD
Dextropropoxyphene—Confusional state—Carmustine—lymphatic system cancer	0.00132	0.00398	CcSEcCtD
Dextropropoxyphene—Visual disturbance—Methotrexate—lymphatic system cancer	0.0013	0.00393	CcSEcCtD
Dextropropoxyphene—Vomiting—Fludarabine—lymphatic system cancer	0.0013	0.00392	CcSEcCtD
Dextropropoxyphene—Convulsion—Mitoxantrone—lymphatic system cancer	0.00129	0.0039	CcSEcCtD
Dextropropoxyphene—Rash—Fludarabine—lymphatic system cancer	0.00129	0.00389	CcSEcCtD
Dextropropoxyphene—Dermatitis—Fludarabine—lymphatic system cancer	0.00129	0.00389	CcSEcCtD
Dextropropoxyphene—Headache—Fludarabine—lymphatic system cancer	0.00128	0.00387	CcSEcCtD
Dextropropoxyphene—Tachycardia—Carmustine—lymphatic system cancer	0.00128	0.00386	CcSEcCtD
Dextropropoxyphene—Discomfort—Mitoxantrone—lymphatic system cancer	0.00126	0.00379	CcSEcCtD
Dextropropoxyphene—Feeling abnormal—Bleomycin—lymphatic system cancer	0.00124	0.00373	CcSEcCtD
Dextropropoxyphene—Confusional state—Mitoxantrone—lymphatic system cancer	0.00123	0.0037	CcSEcCtD
Dextropropoxyphene—Nervous system disorder—Vincristine—lymphatic system cancer	0.00123	0.0037	CcSEcCtD
Dextropropoxyphene—Hypotension—Carmustine—lymphatic system cancer	0.00123	0.00369	CcSEcCtD
Dextropropoxyphene—Nausea—Fludarabine—lymphatic system cancer	0.00122	0.00367	CcSEcCtD
Dextropropoxyphene—Shock—Mitoxantrone—lymphatic system cancer	0.0012	0.00361	CcSEcCtD
Dextropropoxyphene—Tachycardia—Mitoxantrone—lymphatic system cancer	0.00119	0.00358	CcSEcCtD
Dextropropoxyphene—Insomnia—Carmustine—lymphatic system cancer	0.00119	0.00357	CcSEcCtD
Dextropropoxyphene—Hypotension—Vincristine—lymphatic system cancer	0.00117	0.00352	CcSEcCtD
Dextropropoxyphene—Dyspnoea—Carmustine—lymphatic system cancer	0.00117	0.00352	CcSEcCtD
Dextropropoxyphene—Somnolence—Carmustine—lymphatic system cancer	0.00117	0.00351	CcSEcCtD
Dextropropoxyphene—Ataxia—Methotrexate—lymphatic system cancer	0.00116	0.0035	CcSEcCtD
Dextropropoxyphene—Liver function test abnormal—Methotrexate—lymphatic system cancer	0.00114	0.00344	CcSEcCtD
Dextropropoxyphene—Hypotension—Mitoxantrone—lymphatic system cancer	0.00114	0.00343	CcSEcCtD
Dextropropoxyphene—Insomnia—Vincristine—lymphatic system cancer	0.00113	0.00341	CcSEcCtD
Dextropropoxyphene—Gastrointestinal disorder—Carmustine—lymphatic system cancer	0.00113	0.00341	CcSEcCtD
Dextropropoxyphene—Constipation—Carmustine—lymphatic system cancer	0.00112	0.00338	CcSEcCtD
Dextropropoxyphene—Hypersensitivity—Bleomycin—lymphatic system cancer	0.00111	0.00333	CcSEcCtD
Dextropropoxyphene—Dyspnoea—Mitoxantrone—lymphatic system cancer	0.00109	0.00327	CcSEcCtD
Dextropropoxyphene—Somnolence—Mitoxantrone—lymphatic system cancer	0.00108	0.00326	CcSEcCtD
Dextropropoxyphene—Gastrointestinal disorder—Vincristine—lymphatic system cancer	0.00108	0.00326	CcSEcCtD
Dextropropoxyphene—Feeling abnormal—Carmustine—lymphatic system cancer	0.00108	0.00326	CcSEcCtD
Dextropropoxyphene—Asthenia—Bleomycin—lymphatic system cancer	0.00108	0.00325	CcSEcCtD
Dextropropoxyphene—Dyspepsia—Mitoxantrone—lymphatic system cancer	0.00107	0.00323	CcSEcCtD
Dextropropoxyphene—Gastrointestinal pain—Carmustine—lymphatic system cancer	0.00107	0.00323	CcSEcCtD
Dextropropoxyphene—Constipation—Vincristine—lymphatic system cancer	0.00107	0.00322	CcSEcCtD
Dextropropoxyphene—Constipation—Mitoxantrone—lymphatic system cancer	0.00104	0.00314	CcSEcCtD
Dextropropoxyphene—Abdominal pain—Carmustine—lymphatic system cancer	0.00104	0.00312	CcSEcCtD
Dextropropoxyphene—Gastrointestinal pain—Vincristine—lymphatic system cancer	0.00102	0.00308	CcSEcCtD
Dextropropoxyphene—Feeling abnormal—Mitoxantrone—lymphatic system cancer	0.001	0.00303	CcSEcCtD
Dextropropoxyphene—Gastrointestinal pain—Mitoxantrone—lymphatic system cancer	0.000997	0.003	CcSEcCtD
Dextropropoxyphene—Abdominal pain—Vincristine—lymphatic system cancer	0.00099	0.00298	CcSEcCtD
Dextropropoxyphene—Hypersensitivity—Carmustine—lymphatic system cancer	0.000966	0.00291	CcSEcCtD
Dextropropoxyphene—Abdominal pain—Mitoxantrone—lymphatic system cancer	0.000964	0.0029	CcSEcCtD
Dextropropoxyphene—Vomiting—Bleomycin—lymphatic system cancer	0.000955	0.00288	CcSEcCtD
Dextropropoxyphene—Drowsiness—Methotrexate—lymphatic system cancer	0.000952	0.00287	CcSEcCtD
Dextropropoxyphene—Rash—Bleomycin—lymphatic system cancer	0.000947	0.00285	CcSEcCtD
Dextropropoxyphene—Dermatitis—Bleomycin—lymphatic system cancer	0.000946	0.00285	CcSEcCtD
Dextropropoxyphene—Asthenia—Carmustine—lymphatic system cancer	0.000941	0.00283	CcSEcCtD
Dextropropoxyphene—Hypersensitivity—Vincristine—lymphatic system cancer	0.000922	0.00278	CcSEcCtD
Dextropropoxyphene—Hepatobiliary disease—Methotrexate—lymphatic system cancer	0.000901	0.00271	CcSEcCtD
Dextropropoxyphene—Hypersensitivity—Mitoxantrone—lymphatic system cancer	0.000898	0.00271	CcSEcCtD
Dextropropoxyphene—Asthenia—Vincristine—lymphatic system cancer	0.000898	0.00271	CcSEcCtD
Dextropropoxyphene—Diarrhoea—Carmustine—lymphatic system cancer	0.000897	0.0027	CcSEcCtD
Dextropropoxyphene—Nausea—Bleomycin—lymphatic system cancer	0.000892	0.00269	CcSEcCtD
Dextropropoxyphene—Asthenia—Mitoxantrone—lymphatic system cancer	0.000875	0.00264	CcSEcCtD
Dextropropoxyphene—Dizziness—Carmustine—lymphatic system cancer	0.000867	0.00261	CcSEcCtD
Dextropropoxyphene—Diarrhoea—Vincristine—lymphatic system cancer	0.000856	0.00258	CcSEcCtD
Dextropropoxyphene—Diarrhoea—Mitoxantrone—lymphatic system cancer	0.000834	0.00251	CcSEcCtD
Dextropropoxyphene—Vomiting—Carmustine—lymphatic system cancer	0.000834	0.00251	CcSEcCtD
Dextropropoxyphene—Dizziness—Vincristine—lymphatic system cancer	0.000828	0.00249	CcSEcCtD
Dextropropoxyphene—Rash—Carmustine—lymphatic system cancer	0.000827	0.00249	CcSEcCtD
Dextropropoxyphene—Dermatitis—Carmustine—lymphatic system cancer	0.000826	0.00249	CcSEcCtD
Dextropropoxyphene—Visual impairment—Methotrexate—lymphatic system cancer	0.000824	0.00248	CcSEcCtD
Dextropropoxyphene—Headache—Carmustine—lymphatic system cancer	0.000822	0.00247	CcSEcCtD
Dextropropoxyphene—Eye disorder—Methotrexate—lymphatic system cancer	0.000799	0.00241	CcSEcCtD
Dextropropoxyphene—Vomiting—Vincristine—lymphatic system cancer	0.000796	0.0024	CcSEcCtD
Dextropropoxyphene—Cardiac disorder—Methotrexate—lymphatic system cancer	0.000793	0.00239	CcSEcCtD
Dextropropoxyphene—Rash—Vincristine—lymphatic system cancer	0.000789	0.00238	CcSEcCtD
Dextropropoxyphene—Dermatitis—Vincristine—lymphatic system cancer	0.000789	0.00238	CcSEcCtD
Dextropropoxyphene—Headache—Vincristine—lymphatic system cancer	0.000784	0.00236	CcSEcCtD
Dextropropoxyphene—Nausea—Carmustine—lymphatic system cancer	0.000779	0.00235	CcSEcCtD
Dextropropoxyphene—Vomiting—Mitoxantrone—lymphatic system cancer	0.000775	0.00234	CcSEcCtD
Dextropropoxyphene—Immune system disorder—Methotrexate—lymphatic system cancer	0.000772	0.00233	CcSEcCtD
Dextropropoxyphene—Mediastinal disorder—Methotrexate—lymphatic system cancer	0.000771	0.00232	CcSEcCtD
Dextropropoxyphene—Rash—Mitoxantrone—lymphatic system cancer	0.000769	0.00232	CcSEcCtD
Dextropropoxyphene—Dermatitis—Mitoxantrone—lymphatic system cancer	0.000768	0.00231	CcSEcCtD
Dextropropoxyphene—Headache—Mitoxantrone—lymphatic system cancer	0.000764	0.0023	CcSEcCtD
Dextropropoxyphene—Malnutrition—Methotrexate—lymphatic system cancer	0.000744	0.00224	CcSEcCtD
Dextropropoxyphene—Nausea—Vincristine—lymphatic system cancer	0.000744	0.00224	CcSEcCtD
Dextropropoxyphene—Nausea—Mitoxantrone—lymphatic system cancer	0.000724	0.00218	CcSEcCtD
Dextropropoxyphene—Vision blurred—Methotrexate—lymphatic system cancer	0.000701	0.00211	CcSEcCtD
Dextropropoxyphene—Convulsion—Methotrexate—lymphatic system cancer	0.000645	0.00194	CcSEcCtD
Dextropropoxyphene—Discomfort—Methotrexate—lymphatic system cancer	0.000626	0.00189	CcSEcCtD
Dextropropoxyphene—Confusional state—Methotrexate—lymphatic system cancer	0.000612	0.00185	CcSEcCtD
Dextropropoxyphene—Nervous system disorder—Methotrexate—lymphatic system cancer	0.000596	0.00179	CcSEcCtD
Dextropropoxyphene—Hypotension—Methotrexate—lymphatic system cancer	0.000568	0.00171	CcSEcCtD
Dextropropoxyphene—Insomnia—Methotrexate—lymphatic system cancer	0.000549	0.00165	CcSEcCtD
Dextropropoxyphene—Dyspnoea—Methotrexate—lymphatic system cancer	0.000542	0.00163	CcSEcCtD
Dextropropoxyphene—Somnolence—Methotrexate—lymphatic system cancer	0.00054	0.00163	CcSEcCtD
Dextropropoxyphene—Dyspepsia—Methotrexate—lymphatic system cancer	0.000535	0.00161	CcSEcCtD
Dextropropoxyphene—Gastrointestinal disorder—Methotrexate—lymphatic system cancer	0.000524	0.00158	CcSEcCtD
Dextropropoxyphene—Feeling abnormal—Methotrexate—lymphatic system cancer	0.000501	0.00151	CcSEcCtD
Dextropropoxyphene—Gastrointestinal pain—Methotrexate—lymphatic system cancer	0.000497	0.0015	CcSEcCtD
Dextropropoxyphene—Abdominal pain—Methotrexate—lymphatic system cancer	0.00048	0.00145	CcSEcCtD
Dextropropoxyphene—Hypersensitivity—Methotrexate—lymphatic system cancer	0.000448	0.00135	CcSEcCtD
Dextropropoxyphene—Asthenia—Methotrexate—lymphatic system cancer	0.000436	0.00131	CcSEcCtD
Dextropropoxyphene—Diarrhoea—Methotrexate—lymphatic system cancer	0.000416	0.00125	CcSEcCtD
Dextropropoxyphene—Dizziness—Methotrexate—lymphatic system cancer	0.000402	0.00121	CcSEcCtD
Dextropropoxyphene—Vomiting—Methotrexate—lymphatic system cancer	0.000386	0.00116	CcSEcCtD
Dextropropoxyphene—Rash—Methotrexate—lymphatic system cancer	0.000383	0.00115	CcSEcCtD
Dextropropoxyphene—Dermatitis—Methotrexate—lymphatic system cancer	0.000383	0.00115	CcSEcCtD
Dextropropoxyphene—Headache—Methotrexate—lymphatic system cancer	0.000381	0.00115	CcSEcCtD
Dextropropoxyphene—Nausea—Methotrexate—lymphatic system cancer	0.000361	0.00109	CcSEcCtD
